ABSTRACT. Group B P-hemolytic streptococcus (GBS) infection is an important cause of neonatal pneumonia and sepsis. GBS infection is frequently associated with persistent pulmonary hypertension of the newborn. To better understand the early pulmonary hypertension phase of GBS-induced acute lung injury in a conscious animal, we characterized the pulmonary and systemic hemodynamic response of spontaneously breathing, chronically instrumented newborn lambs to injections of heat-killed type Ib GBS, 0.1-9.0 x lo9 colony forming units. Heat-killed GBS caused marked dose-dependent increases in mean pulmonary arterial pressure and calculated pulmonary vascular resistance, 190 and 370% at the maximum dose, respectively. Similarly, GBS caused dose-dependent increases in mean systemic arterial pressure and systemic vascular resistance (28.5 and 108% at the maximum dose, respectively) and a decrease in cardiac output (33.5%). Arterial oxygen tension worsened at the higher doses. GBS-induced pulmonary hypertension was decreased by two structurally unrelated, putative leukotriene D4 receptor antagonists. Pretreatment with LY171883 blocked GBS-induced pulmonary hypertension by 95%, and WY48,252 attenuated this effect by 27%. Both drugs completely blocked the hemodynamic effects of exogenous leukotriene D4. For comparison, several lambs received bolus injections of live GBS, either alone or after pretreatment with LY171883. The hemodynamic response to live GBS and attenuation of that response by LY171883 were similar to those caused by similar doses of heat-killed GBS. Thus, bolus injections of heat-killed GBS provide a reproducible model of pulmonary hypertension in conscious newborn lambs. In addition, the sulfidopeptide leukotrienes appear to be important mediators of GBS-induced pulmonary hypertension in newborn lambs. (Pediatr Res 31: 121-126, 1992 GBS infection is a major cause of neonatal pneumonia and sepsis. The overall mortality of GBS sepsis is reported to be as high as 50%. GBS infection is frequently associated with persistent pulmonary hypertension of the newborn and is an important cause of neonatal mortality (1, 2). The clinical and experimental cardiopulmonary effects of GBS are very similar to those seen in gram-negative sepsis (3-10). Numerous reports have demonstrated the importance of the cyclooxygenase products of arachidonic acid metabolism, especially TXA2, in the pathogenesis of GBS-induced pulmonary hypertension (1 0-13). Limited information is available regarding the importance of the lipoxygenase products of arachidonic acid metabolism, specifically the vasoactive sulfidopeptide L T C and D4 in GBS-induced pulmonary hypertension (4, 8) .
GBS infection is a major cause of neonatal pneumonia and sepsis. The overall mortality of GBS sepsis is reported to be as high as 50%. GBS infection is frequently associated with persistent pulmonary hypertension of the newborn and is an important cause of neonatal mortality (1, 2) . The clinical and experimental cardiopulmonary effects of GBS are very similar to those seen in gram-negative sepsis (3) (4) (5) (6) (7) (8) (9) (10) . Numerous reports have demonstrated the importance of the cyclooxygenase products of arachidonic acid metabolism, especially TXA2, in the pathogenesis of GBS-induced pulmonary hypertension (1 0-13). Limited information is available regarding the importance of the lipoxygenase products of arachidonic acid metabolism, specifically the vasoactive sulfidopeptide L T C and D4 in GBS-induced pulmonary hypertension (4, 8) .
The purposes of the present study were to characterize the hemodynamic response of spontaneously breathing, chronically instrumented newborn lambs to injections of heat-killed GBS and to investigate the contribution of LTD4 to GBS-induced pulmonary hypertension. The latter was studied by pretreating lambs with one of two structurally unrelated, putative LTD4 receptor antagonists ( Fig. 1 ): LY171883 (Lilly Research Laboratory, Indianapolis, IN) or WY 48,252 (Wyeth-Ayerst Research, Princeton, NJ). In addition, studies were performed using live GBS to verify that the response to heat-killed GBS was not caused by the processing of the bacteria.
MATERIALS AND METHODS
Surgical Preparation. Twenty-four newborn lambs, less than a week of age, were instrumented under general anesthesia, which was induced by having the lambs breathe a mixture of oxygen and isoflurane. The lambs were intubated with a 4.5-mm inner diameter endotracheal tube and mechanically ventilated with an animal ventilator. Anesthesia was maintained with 1-2% isoflurane. Polyvinyl catheters were placed under direct visualization into a hindlimb artery and vein and advanced into the descending aorta and inferior vena cava, respectively. A left lateral thoracotomy was performed in the fourth intercostal space, and the pericardium was incised. Polyvinyl catheters were then placed into the internal thoracic artery and vein and advanced into the ascending aorta and right atrium, respectively. Polyvinyl catheters were placed into the main pulmonary artery and left atrium.
An appropriately sized (7.5-to 1 1 .O-mm internal diameter), in vitro calibrated electromagnetic flow transducer (Carolina Medical Electronics, Inc., King, NC) was placed around the main pulmonary artery trunk to measure cardiac output. The ductus arteriosus was ligated. A chest tube was placed into the pleural space to drain air and fluid postoperatively. The thoracotomy incision was closed in layers. The catheters were filled with heparin, plugged, and, along with the transducer cable, brought SCHREIBE IR ET AL.
to the skin and secured to the lamb's flank. The lamb was then weaned from mechanical ventilation, and, after recovery from anesthesia, returned to its mother. At least 3 d were allowed for recovery before any studies were performed. Lambs received daily intramuscular injections of gentamicin sulfate.
This protocol was approved by the Institutional Animal Care and Use Committee.
Measurements and Analyses. Pulmonary and systemic arterial and right and left atrial pressures were measured using Statham 23Db pressure transducers. Mean pressures were obtained by electrical integration. Cardiac output was measured using an electromagnetic flowmeter (Carolina Medical Electronics, Inc.). All hemodynamic variables were continuously recorded on an eight-channel direct-writing recorder (Gould Electronics, Cleveland, OH). Systemic arterial pH and blood gas tensions were measured using a Radiometer ABL 30 acid-base blood gas analyzer (Radiometer, Inc., Copenhagen, Denmark). PVR and SVR were calculated per kg using standard formulas.
The means and SD were calculated for the hemodynamic variables and systemic arterial pH and blood gas tensions during each of the experimental conditions and were compared using two-way analysis of variance and the Scheffe t test for multiple comparisons, the Wilcoxon paired test, paired t tests, or linear regression analysis, as appropriate. A p value <0.05 was considered statistically significant (14) .
Experimental Protocol. Heat-killed GBS dose-response studies. To determine the pulmonary and systemic hemodynamic effects of heat-killed GBS, six lambs received multiple doses (0.1, 0.25, 0.5, 1.0,3.0,6.0, and 9.0 x lo9 cfu) of GBS during a single study day. The maximal dose given varied in that 6-9 x lo9 cfu could not be given to every lamb because cardiac output fell so significantly that higher doses might have caused death.
Based on preliminary data, GBS injections were given at least 20 min apart to prevent tachyphylaxis. In addition to the above doses, lambs received several doses of 1 x lo6 cfu GBS throughout the study day to determine whether the hemodynamic response to a single repeated dose of GBS changed after multiple injections.
LTD, and L T receptor antagonism. To determine whether the LTD, receptor antagonists LY 171883 and WY 48,252 block the hemodynamic effects of exogenous LTD,, lambs were injected with LTD4 before and after treatment with one of these two drugs.
Baseline measurements were made, as above, while the lambs were breathing spontaneously and resting in a sling. Lambs then received an i.v. injection of LTD4, 1 pg/kg, which served as a control injection, and the effects were recorded. At least 30 min later, lambs received either LY 17 1883 (20 mg/kg, n = 7 lambs) or WY 48,252 (30 mg/kg, n = 8 lambs). The dose of LTD4 was repeated, and the effects were again recorded.
GBS and LT receptor antagonism. Heat-killed GBS. To determine the contribution of LT to the hemodynamic changes caused by GBS injection, one of two putative LTD4 receptor antagonists; LY171883 or WY 48,252, was studied. Baseline measurements were made, as above, while the lambs were breathing spontaneously and resting in a sling. Lambs then received an i.v. injection of 1 x lo9 cfu of heat-killed GBS, which served as a control injection, and the effects were recorded. This GBS dose was chosen because it caused a reproducible 50-100% increase in mean pulmonary arterial pressure with minimal systemic hemodynamic effects. Thirty min later, lambs received either LY171883 (20 mg/kg, n = 7 lambs) or WY 48,252 (30 mg/kg, n = 8 lambs). Before repeating the dose of 1 x lo9 CFU of heatkilled GBS, LT blockade was confirmed by injecting exogenous LTD4 (1 pglkg). The effects were again recorded.
Live GBS. To determine whether the hemodynamic response to heat-killed GBS was similar to the response to live bacteria, three lambs received an injection of live GBS before and after pretreatment with LY 17 1883. The lambs received two injections of live GBS, one alone and the other after pretreatment with LY 17 1883 (20 mg/kg). Injections were separated by at least 48 h. While the lambs rested in a sling, baseline hemodynamic variables and arterial pH and blood gas tensions were measured. The hemodynamic variables were recorded before and after LY 17 1883 or saline control and before and after live GBS (1 x lo9 cfu) was injected. Arterial pH and blood gas tension measurements were repeated 5 and 20 min after live GBS injection. Lambs received parenteral antibiotics after each day's study and were clinically well before receiving a second injection of live GBS.
Left atrial injection of GBS. To determine whether the effect of GBS on the pulmonary circulation was greater than that on the systemic circulation because of a "first-pass" phenomenon by which GBS may have its greatest effect at the first capillary bed encountered, we compared GBS injections into the inferior vena cava with injections into the left atrium.
On a separate study day, three lambs received injections of heat-killed GBS (1 x lo9 cfu): two into the inferior vena cava, and two into the left atrium. Hemodynamic measurements were made before and after injections of GBS and at least 20 min were allowed between injections. The order of injections was randomly assigned.
GBS and Drug Preparations. GBS, type Ib, was isolated from the blood of a newborn infant who developed early-onset sepsis at the University of Chicago Intensive Care Nursery. Bacteria were grown in Todd-Hewitt broth for 18-36 h at 37°C to late log phase and harvested by centrifugation at 5000 rpm for 15 min. Bacteria were resuspended in sterile normal saline to a concentration determined by serial viable counts to be 1 x lo9 cfu/mL. Live bacteria were used on the day of harvesting. Heat-killed bacteria were obtained by heating bacteria to 60°C for 60 min. GBS killing was confirmed by no growth on blood agar. Aliquots of heat-killed GBS were stored at -70°C until the study day. Mean SAP and calculated SVR also increased in a dosedependent manner ( p < 0.005, Fig. 3 
-
arterial pH or blood gas tensions, although oxygenation tended to decrease at the highest dose that each lamb received; arterial O2 pressure decreased from 11.2 (1.7 SD) to 9.9 (1.6 SD) kPa ( p = 0.07).
No attenuation or potentiation of the GBS-induced hemodynamic effects was observed when multiple doses were given throughout the day.
LTD4 and LT Receptor Antagonism. Intravenous injection of LTD4 (1.0 pg/kg) caused a significant increase in PAP and SAP and a decrease in cardiac output. These effects were completely blocked by both LY171883 and WY 48,252 (Fig. 4) . GBS and L T Receptor Antagonism. Heat-killed GBS. LY 17 1883 caused no changes in the baseline value of hemodynamic variables. It did, however, completely block the heat-killed GBS-induced increase in PAP ( p < 0.000 1, Fig. 5 ). The control injection of GBS, 1.0 x lo9 cfu, increased PAP 100% from 18 to 36 mm Hg. After pretreatment with LY 17 1883, PAP increased 5% from 18 to 19 mm Hg. In addition, LY 171883 significantly attenuated the GBS-induced systemic hypertension and decrease in cardiac output ( p < 0.05).
Intravenous injection of WY 48,252 caused a transient increase in PAP, which returned to baseline values before the injection of heat-killed GBS. This was believed to be secondary to the ethanol vehicle, inasmuch as ethanol alone also caused a tension associated with an increase in protein-rich lung lymph flow that is indicative of pulmonary endothelial injury. This study predominantly investigated the early pulmonary hypertensive phase of GBS-induced lung injury. Because tachyphylaxis or potentiation, which has been reported when small doses are repeated (6, 8) , has been observed, we verified that equal doses of GBS given during the same day would cause similar effects.
The first or early phase of GBS-induced and endotoxin-induced pulmonary hypertension is generally believed to be mediated by TXA2. Both cyclooxygenase synthesis inhibition and thromboxane synthesis inhibition decrease the GBS and endotoxin-induced increase in TXB2 (the measurable metabolite of TXA2) concentration and the increase in PAP (10-1 3) . Because of the strong interaction between the cyclooxygenase and lipoxygenase pathways of arachidonic acid metabolism (1 5-18), we were interested in whether TXA2 is the sole mediator or whether an interaction between TXA2 and the sulfidopeptide LT exists. Previous studies have reported that TXA2 can cause an increase in L T C and LTD4 production (17) . A recent study suggests that TXA2-induced pulmonary hypertension is partially mediated through sulfidopeptide LT (1 8) .
The contribution of sulfidopeptide LT to GBS-inducted pulmonary vasoconstriction in anesthetized piglets has been previously reported by Goldberg et al. (4) . They demonstrated that the putative LT receptor antagonist FPL5723 1 blocks the early phase of GBS-induced pulmonary hypertension. Additional evidence that LT are involved in the control of the pulmonary circulation includes: FPL5723 1 blocking hypoxia-induced pulmonary hypertension in newborn (1 9) and adult sheep (20) , oleic acid-induced pulmonary hypertension in newborn lambs (21), and TXA2 mimetic-induced pulmonary hypertension in newborn lambs (1 8), and FPL5723 1 dramatically increasing pulmonary blood flood flow in fetal sheep (22). The importance of LT has been supported using lipoxygenase synthesis inhibition to attenuate hypoxia-induced pulmonary hypertension in newborn lambs (23) and to increase pulmonary blood flow in fetal sheep (1 5). However, the reported nonspecific vasodilating properties of FPL5723 1 have always been a confounding factor (24) .
The possible contribution of sulfidopeptide LT to the hemodynamic effects of E. coli endotoxin has previously been reported in adult sheep (25, 26), adult cats (27), and pigs (28), with conflicting results. In adult sheep, the sulfidopeptide LT receptor antagonist FPL5723 1 blocked the endotoxin-induced increase in PAP and pulmonary vascular pressure (25). Similar results were found in adult cats using slightly higher doses of FPL5723 1 (27). Although these results could be interpreted as caused by nonspecific pulmonary vasodilation caused by FPL5723 1, LY 1 7 1 883 also attenuated endotoxin-induced pulmonary hypertension in adult sheep (26) and to a lesser extent in anesthetized pigs (28). These data, along with our data, suggest that species, age, and methodologic differences, such as anesthesia, play important roles.
By using two unrelated putative LTD4 receptor antagonists (16), we addressed this methodologic concern (Fig. 1) . LTD4 receptor antagonists were selected because previous studies have shown that LTD4, not LTC4, is responsible for LT-induced pulmonary hypertension in newborn lambs (29). LY171883 completely blocked GBS-induced pulmonary hypertension; WY 48,252 attenuated this response. At least two possible explanations account for the relative difference between these two drugs. First, LY 17 1883 may have other properties besides LTD4 receptor antagonism. In high doses, LY171883 has been reported to be a phosphodiesterase inhibitor. In addition, at very high doses, higher than those used in this study, LY171883 is a relatively weak TX receptor antagonist (16, 30) . Given the known importance of TXA2 in the early phase of GBS-induced pulmonary hypertension, this may have been an important factor. Second, although administered in nearly equimolar amounts, the bioavailability of these two drugs may differ.
WY 48,252 has previously been shown to block LTD4 and (32) . Although phosphodiesterase inhibition appears to be the major difference in mechanism of action between LY171883 and WY 48,252, this is unlikely to be the cause for the differences seen between these two drugs. LY171883, previously shown to block exogenous LTD4 in adult pigs (17) , does not attenuate endotoxininduced bronchoconstriction (28), and our preliminary data demonstrate that aminophylline does not attenuate GBS-induced pulmonary hypertension (33). The sulfidopeptide LT are produced by a variety of cells within the lung, including mast cells, alveolar macrophages, type I1 pneumocytes, and pulmonary vascular tissue (34-36). LT from these sources can be rapidly synthesized within the lung (36). They cause both arterial and venous constriction (37). Although LT concentrations have never been measured immediately (1-2 min) after lung insult, primarily because of methodologic difficulties (38), previous work in newborn lambs has shown the rapid onset of effect of LTD4 on the pulmonary and systemic circulations (29).
Because the major focus of this study was to attenuate the pulmonary hypertension induced by GBS, we chose a dose of GBS that caused predominantly pulmonary vascular changes with minimal systemic vascular effects. This strategy was used because the predominant morbidity and mortality from GBSinduced pulmonary hypertension seen clinically is severe pulmonary vasoconstriction with resultant severe hypoxemia. Other newborn infants, however, do sustain significant systemic vascular alterations when infected with GBS. Some investigators have suggested that the pulmonary vasculature of the newborn is more sensitive to vasoactive substances than the systemic circulation (39). If true, this could be due to more active conversion of L T C to LTD4 in the newborn. Other studies have suggested that the perinatal metabolism differs from the mature metabolism of arachidonic acid (40). Alternatively, in our study, GBS could have had predominantly pulmonary vascular effects because, when injected i.v., the pulmonary capillary bed received the highest concentration during the first pass. To test this possibility, we injected GBS into the left atrium of several lambs and found the systemic and pulmonary effects to be similar.
The documentation that heat-killed GBS causes similar hemodynamic changes with common mediators to live GBS is important. Multiple doses of heat-killed GBS can be administered without the concern for potential effects of live bacteria continuing to multiply within the host. Live bacteria must be grown immediately before use. Some variability in colony count may occur. Heat-killed bacteria may be stored for long periods of time, allowing serial studies to use the identical bacteria concentration. In addition, administration of antibiotics is not required, and the biohazard potential to laboratory staff is greatly reduced.
In conclusion, small bolus injections of heat-killed GBS may be a useful model to study the early pulmonary hypertensive phase of GBS-induced acute lung injury. In our conscious newborn lamb model, the pulmonary hypertension is mediated, in part, through sulfidopeptide LT. Modulation of LT may, therefore, be clinically important in the treatment of newborn infants with GBS-induced pulmonary hypertension.
